UPDATE: H.C. Wainwright Starts Valneva SE (VALN) at Buy

August 3, 2022 6:09 AM EDT
Get Alerts VALN Hot Sheet
Price: $11.59 +0.43%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 9 | New: 24
Join SI Premium – FREE
(Updated - August 3, 2022 6:27 AM EDT)

H.C. Wainwright analyst Edward White initiates coverage on Valneva SE (NASDAQ: VALN) with a Buy rating and a price target of $34.00.

The analyst comments "Promising specialty vaccine company with a solid cash position. Valneva is a fully integrated specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet need. The company has three vaccine development programs as well as two commercially available vaccines for travelers. While there has been a lot of focus on the COVID-19 vaccine opportunity, we are not including that program in our valuation due to uncertainty regarding European contracts; we still believe the current stock price represents a buying opportunity when considering only the Lyme disease and chikungunya opportunities. As of March 31, 2022, Valneva had a cash balance of €311.3 million. We are initiating coverage of Valneva with a Buy rating and $34 price target."

For an analyst ratings summary and ratings history on Valneva SE click here. For more ratings news on Valneva SE click here.

Shares of Valneva SE closed at $19.84 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, New Coverage

Related Entities

H.C. Wainwright